Prof. Müller-Tidow zeigt am PC

Individual treatment offer

For our medical specialists to check if a treatment option / appointment is possible, submit your data here.

Treatment inquiry & Appointment

Request Your Online Second Opinion

We offer remote second opinion services for patients with leukemia, lymphoma, multiple myeloma (written report or videoconsultation).

Contact Form
Diseases & Treatments … Cancer & Tumors Hematology, Oncology…

Department of Hematology, Oncology and Rheumatology

Best treatment options and cutting-edge research

At Heidelberg University Hospital, with over 300 stem cell transplants annually, you will find one of the largest and most renowned centers for hematology, oncology and rheumatology in Europe. Under the direction of Professor Dr. Carsten Müller-Tidow has put together a highly specialized team of doctors and scientists who have extensive experience, especially in the treatment of multiple myeloma, leukemia and lymphoma.

[Translate to English:] Portrait von Prof. Dr. med. Carsten Müller-Tidow
Prof. Dr. med. Carsten Müller-Tidow

Our Therapeutic Specializations

  • Multiple myeloma
  • Acute leukemia 
  • Chronic myelogenous leukemia (CML) and other myeloproliferative neoplasms
  • Chronic lymphocytic leukemia and hairy cell leukemia
  • Lymphoma (Hodgkin's lymphoma and non-Hodgkin's lymphoma)
  • Sarcoma

CAR T Cell therapy

We offer CAR T cell therapy in acute leukemia and for the treatment of lymphoma. In this cell therapy, immune system cells (T cells) are genetically re-programmed so that they destroy the tumor cells. We would be happy to inform you whether this type of therapy might also offer promising results for your case.

Further information:

At a glance: this distinguishes us

  • Personal care of our 2700 patients per year
  • Close integration of research and patient care allows therapies of the future
  • Avoiding inpatient stays even for patients with malignant diseases. Close integration of our outpatient clinics and day hospital.
  • 30 specialists in Hematology and Oncology cooperate with other physician teams of the University Hospital
  • Our own bone marrow and stem-cell transplantation Station with around 300 stem cell transplantations per year
  • 2700

    patients / year
  • 300

    stem cell transplantations / year

Therapies of the future available today

The close integration of clinical care and research enables us to offer innovative, promising therapies. We use the latest medications, often in clinical trials that are not yet applied in routine practice, however, often deliver very promising effects.

Innovative therapies with the most promising effects

  • Autologous stem-cell transplantation 
    This form of therapy is particularly suitable for patients with patients with multiple myeloma. Treatment is sometimes even possible as an outpatient (treatment period approx. 4 weeks)
  • Allogeneic stem-cell transplantation (treatment period approx. 3 months)
  • Chemotherapy and Immunotherapy, including CAR T cell therapy
  • Innovative and classical radiation (Dep. for Radiooncology)
  • Radioimmunotherapy
  • Tumor vaccination

Pioneering research: Target-oriented treatment through comprehensive knowledge

Since 1985, when one of the world's first stem cell transplantations was performed here, Heidelberg has played a pioneering role in stem cell research. Among other things, our physicians work on leukemia and lymphoma research. The research and production of novel cell therapies and vaccines is one specialization of our department. Close cooperation of our hospital with the German Cancer Research Center and the National Center for Tumor Diseases underscores the strength of Heidelberg research.

Our own bone marrow and stem-cell transplantation ward

Special immune system protection

Hematology Heidelberg smiling doctor in consultation

One of our special features is our own bone marrow and stem cell transplantation ward with 18 patient rooms. These are equipped with "HEPA filters": the air is specially filtered to minimize the risk of infection for our immunocompromised patients. 

For the same reason, there are no long transport distances for our patients between different wards: the intensive care unit is integrated into the stem cell transplantation unit.

At the highest level: Comprehensive care by our specialists

In the Department of Hematology, a large specialist team of more than 30 physicians is available to our patients. These experts come together with colleagues from other departments at the "Tumor Board," where they discuss each particular case and develop an individualized treatment plan. In this way, we find the best possible - and above all, the most promising - therapy for each Patient.

  • Portrait von Prof. Dr. med. Carsten Müller-Tidow

    It is very important for me to provide individual treatments for each patient while taking into account latest research findings. This is how we ensure best possible treatment results for all of our patients.

    Professor Dr. Carsten Müller-Tidow, Medical Director of the Department of Hematology, Oncology, and Rheumatology

Related Press Releases

Department of Hematology, Oncology, Rheumatology

  • CAR T-cell therapy starts in Germany


    Heidelberg is the first center to offer CAR T-cell therapy in Germany | New cell therapy procedure to treat rare leukemias and lymphomas | Natural immune cells “learn” to attack tumor cells.

    Read Article
  • Heidelberg hematologist receives cancer award


    Prof. Dr. Hartmut Goldschmidt has been awarded the German Cancer Award for the research and therapy optimization of multiple myeloma.

    Read Article
  • More than 30 years of stem cell transplants


    More than 30 years ago, the first patient at Heidelberg University Hospital was treated with stem cells from his own blood, one of the first stem cell transplants worldwide at the time. Today, Heidelberg is one of the largest centers of this kind in the world with over 300 transplants per year.

    Read Article